Abstract
Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi / nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory / fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.
Keywords: Aldosteronism, cardiac cachexia, Fibrogenic
Current Drug Targets
Title: Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Volume: 4 Issue: 6
Author(s): Karl T. Weber, Ivan C. Gerling, Mohammad F. Kiani, Ramareddy V. Guntaka, Yao Sun, Robert A. Ahokas, Arnold E. Postlethwaite and Kenneth J. Warrington
Affiliation:
Keywords: Aldosteronism, cardiac cachexia, Fibrogenic
Abstract: Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi / nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory / fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.
Export Options
About this article
Cite this article as:
Weber T. Karl, Gerling C. Ivan, Kiani F. Mohammad, Guntaka V. Ramareddy, Sun Yao, Ahokas A. Robert, Postlethwaite E. Arnold and Warrington J. Kenneth, Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets, Current Drug Targets 2003; 4 (6) . https://dx.doi.org/10.2174/1389450033490948
DOI https://dx.doi.org/10.2174/1389450033490948 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Therapy for Myocardial Repair
Current Cardiology Reviews Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Application of Carbon Monoxide for Transplantation
Current Pharmaceutical Biotechnology Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Postoperative Thoracic Epidural Anesthesia in Gastrointestinal Surgery: Outcomes, Quality of Life, and Current Controversies
Current Drug Therapy From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry COMPLICATIONS OF RECANALIZATION OF CHRONIC TOTAL OCCLUSION
Current Cardiology Reviews There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Oxygen Free Radicals and Their Biomedical Implications: A Mini Review
Mini-Reviews in Organic Chemistry A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery